Humacyte Statistics
Share Statistics
Humacyte has 713.68M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 713.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 44 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 3.92K, so 0% of the outstanding
shares have been sold short.
| Short Interest | 3.92K |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -4.02 and the forward
PE ratio is null.
Humacyte's PEG ratio is
-0.23.
| PE Ratio | -4.02 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 5.4 |
| PB Ratio | -11.36 |
| P/FCF Ratio | -6 |
| PEG Ratio | -0.23 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Humacyte.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.4,
with a Debt / Equity ratio of -0.31.
| Current Ratio | 2.4 |
| Quick Ratio | 2.4 |
| Debt / Equity | -0.31 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.17 |
| Interest Coverage | -12.33 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-682,114.68 |
| Employee Count | 218 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -68.57% in the
last 52 weeks. The beta is 1.64, so Humacyte's
price volatility has been higher than the market average.
| Beta | 1.64 |
| 52-Week Price Change | -68.57% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 1.38 |
| Relative Strength Index (RSI) | 57.53 |
| Average Volume (20 Days) | 30,056 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -114.4M |
| Net Income | -148.7M |
| EBITDA | -132.23M |
| EBIT | -139.42M |
| Earnings Per Share (EPS) | -1.26 |
Full Income StatementBalance Sheet
The company has 44.94M in cash and 16.54M in
debt, giving a net cash position of 28.4M.
| Cash & Cash Equivalents | 44.94M |
| Total Debt | 16.54M |
| Net Cash | 28.4M |
| Retained Earnings | -686.01M |
| Total Assets | 162.55M |
| Working Capital | 53.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -98.12M
and capital expenditures -1.57M, giving a free cash flow of -99.69M.
| Operating Cash Flow | -98.12M |
| Capital Expenditures | -1.57M |
| Free Cash Flow | -99.69M |
| FCF Per Share | -0.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
